Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 4, 2026
Reporting Period: First Quarter ended March 31, 2026
This filing announces the financial results for the first quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not explicitly stated in the Form 8-K cover document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing serves as a notification of the Q1 2026 results announcement. Specific management commentary, guidance, or outlook is not included in the text of this Form 8-K.
Risks and Contingencies: No specific risks or contingencies are detailed in this document. The filing includes a standard disclaimer stating that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for updated full-year 2026 financial guidance within the press release.
- Confirm any new product approvals, clinical trial updates, or regulatory developments mentioned in the press release.